Can Cannabinoid CB2 Receptor Antagonist Combined With KEYTRUDA Be Effective In Patients With Advanced Solid Tumors? These Two Companies Aim To Find Out
Teon Therapeutics a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and development of G-Protein Coupled Receptor immuno-oncology therapies in difficult-to-treat cancers, has entered into the clinical trial collaboration agreement with Merck (NYSE: